Ghisallo Capital Management LLC Invests $146,000 in Augmedix, Inc. (NASDAQ:AUGX)

Ghisallo Capital Management LLC acquired a new position in shares of Augmedix, Inc. (NASDAQ:AUGX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $146,000. Ghisallo Capital Management LLC owned 0.06% of Augmedix as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of Augmedix by 292.0% in the fourth quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock valued at $5,213,000 after buying an additional 663,778 shares in the last quarter. Boston Partners lifted its stake in shares of Augmedix by 33.6% in the fourth quarter. Boston Partners now owns 84,036 shares of the company’s stock valued at $492,000 after buying an additional 21,157 shares in the last quarter. Jump Financial LLC lifted its position in shares of Augmedix by 82.6% during the fourth quarter. Jump Financial LLC now owns 68,308 shares of the company’s stock valued at $400,000 after purchasing an additional 30,900 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Augmedix during the third quarter valued at about $2,237,000. Finally, Calamos Advisors LLC bought a new position in shares of Augmedix during the fourth quarter valued at about $886,000. 87.11% of the stock is currently owned by institutional investors and hedge funds.

Augmedix Price Performance

AUGX stock traded up $0.03 during midday trading on Friday, reaching $0.85. The company had a trading volume of 279,928 shares, compared to its average volume of 1,513,267. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.04 and a quick ratio of 2.04. Augmedix, Inc. has a 1 year low of $0.73 and a 1 year high of $6.25. The company has a market capitalization of $41.74 million, a P/E ratio of -1.98 and a beta of -0.27. The firm has a 50-day moving average price of $2.39 and a 200-day moving average price of $3.97.

Augmedix (NASDAQ:AUGX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Augmedix had a negative net margin of 41.95% and a negative return on equity of 178.34%. The business had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $13.25 million. On average, research analysts anticipate that Augmedix, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Evercore ISI lowered shares of Augmedix from an “outperform” rating to an “inline” rating and dropped their price target for the company from $5.00 to $1.50 in a research report on Tuesday, May 14th. Maxim Group lowered shares of Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price objective on the stock. in a research report on Tuesday, May 14th. B. Riley started coverage on shares of Augmedix in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price objective on the stock. Finally, Lake Street Capital lowered their price objective on shares of Augmedix from $8.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, May 14th.

Insider Activity at Augmedix

In related news, insider Ian Shakil sold 58,978 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $3.91, for a total transaction of $230,603.98. Following the completion of the sale, the insider now directly owns 180,034 shares in the company, valued at approximately $703,932.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 260,359 shares of company stock worth $1,016,280 in the last three months. 10.97% of the stock is owned by insiders.

Augmedix Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.